Equity Details
Price & Market Data
Price: $7.74
Daily Change: -$0.15 / 1.94%
Daily Range: $7.67 - $8.14
Market Cap: $651,316,544
Daily Volume: 224,457
Performance Metrics
1 Week: -1.69%
1 Month: -9.16%
3 Months: -25.00%
6 Months: -33.09%
1 Year: -25.07%
YTD: -35.06%
About BridgeBio Oncology Therapeutics, Inc. (BBOT)
Uncover market data for BridgeBio Oncology Therapeutics, Inc. (BBOT). Price: 7.74, daily change: -$0.15 / 1.94%. Market cap: 651,316,544. Performance from 1-week to 6-month.
Company Details
Employees: 92
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.